{
    "clinical_study": {
        "@rank": "63954", 
        "arm_group": [
            {
                "arm_group_label": "efatutazone and paclitaxel", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive efatutazone 0.5 mg PO twice daily in combination with paclitaxel 175 mg/m2  IV day 1 of an every 21 day cycle. Please note that patients receive efatutazone continuously with no break between cycles. Treatment will continue until disease progression, unacceptable adverse events or a minimum of 2 cycles beyond a complete response."
            }, 
            {
                "arm_group_label": "paclitaxel", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients receive paclitaxel 175 mg/m2  IV day 1 of an every 21 cycle. Treatment will continue until disease progression, unacceptable adverse events or a minimum of 2 cycles beyond a complete response."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized phase II trial studies how well efatutazone with paclitaxel compared to\n      paclitaxel alone works in treating patients with advanced anaplastic thyroid cancer. Drugs\n      used in chemotherapy, such as efatutazone and paclitaxel, work in different ways to stop the\n      growth of tumor cells, either by killing the cells by stopping them from dividing or by\n      stopping them from spreading. It is not yet known whether efatutazone in combination with\n      paclitaxel is more effective than paclitaxel alone in treating patients with advanced\n      anaplastic thyroid cancer."
        }, 
        "brief_title": "Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer", 
        "condition": [
            "Anaplastic Thyroid Cancer", 
            "Recurrent Thyroid Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Thyroid Neoplasms", 
                "Thyroid Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 2 randomized study of efatutazone with paclitaxel compared to paclitaxel\n      alone. Patients are randomized to one of two treatment arms, efatutazone in combination with\n      paclitaxel or paclitaxel alone. Protocol therapy will consist of continuous cycles\n      administered every 21 days. Treatment will continue until disease progression, unacceptable\n      adverse events, or a minimum of two cycles beyond a complete response. The primary and\n      secondary objectives are listed below.\n\n      Primary objective:\n\n      To determine if the combination of paclitaxel and efatutazone improves overall survival (OS)\n      compared to paclitaxel alone in patients with advanced anaplastic thyroid cancer.\n\n      Secondary objective:\n\n      To compare the confirmed response rate, duration of response, progression-free survival\n      (PFS), and adverse event rates between the combination of paclitaxel and efatutazone vs.\n      paclitaxel alone.\n\n      Patients will be followed for every 6 months until 5 years after registration."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "1. Documentation of Disease - Patients must have histologically or cytologically\n             diagnosed advanced anaplastic thyroid cancer (ATC).\n\n          2. Patients must have measurable disease as defined in the protocol.\n\n          3. Patients must have either metastatic (stage IVC) or locally advanced unresectable\n             disease (stage IVB).\n\n          4. Prior Treatment:\n\n               -  Patients should have resolution of any toxic effects of prior therapy (except\n                  alopecia) to NCI CTCAE, Version 4.0, grade 1.\n\n               -  There is no limit to the number of prior lines of treatment a patient has\n                  received.\n\n               -  No treatment with chemotherapy, radiation therapy, immunotherapy, biological\n                  therapy, hormonal therapy, or other thiazolidinediones (TZDs) \u2264 28 days before\n                  study registration.\n\n               -  No prior taxane therapy \u2264 6 months, except as a radiosensitizer.\n\n          5. No history of the following:\n\n               -  Class III or IV congestive heart failure (CHF)\n\n               -  Grade 3 or 4 thromboembolic event \u2264 6 months\n\n               -  Pericardial effusion \u2264 12 months (any grade)\n\n               -  Pericardial involvement with tumor\n\n               -  Grade 2 or higher pleural effusion \u2264 6 months\n\n          6. No current symptomatic, untreated, or uncontrolled brain metastases present\n\n          7. No major surgery \u2264 28 days prior to registration\n\n          8. No grade 2 or higher neuropathy\n\n          9. No known history of severe hypersensitivity reactions to any of the components of\n             efatutazone or paclitaxel formulations\n\n         10. Not pregnant and not nursing, because this study involves an agent that has known\n             genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing\n             potential only, a negative pregnancy test done \u2264 7 days prior to registration is\n             required\n\n         11. Age \u2265 18 years\n\n         12. Concomitant Medications:\n\n               -  Patients with diabetes mellitus requiring concurrent treatment with insulin or\n                  thiazolidinedione (TZD) oral agents are not eligible.\n\n               -  Patients with known hypersensitivity to any TZD oral agents are not eligible.\n\n         13. Eastern Cooperative Oncology Group (ECOG) Performance Status  \u2264 2\n\n         14. Required Initial Laboratory Values:\n\n               -  Absolute Neutrophil Count (ANC)  \u2265 1,500/mm3\n\n               -  Platelet Count                                  \u2265 100,000/mm3\n\n               -  Creatinine                                          \u2264 1.5 x ULN (Upper Limit of\n                  Normal) mg/dL OR\n\n               -  Calculated Creatinine Clearance  \u2265 60 mL/min\n\n               -  Bilirubin                                          \u2264 1.5 x ULN\n\n               -  Aspartate aminotransferase (AST)  \u2264 2.5 x ULN"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02152137", 
            "org_study_id": "A091305", 
            "secondary_id": [
                "U10CA031946", 
                "U10CA180821", 
                "NCI-2014-00686"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "efatutazone and paclitaxel", 
                "description": "Given PO", 
                "intervention_name": "efatutazone", 
                "intervention_type": "Drug", 
                "other_name": "CS-7017"
            }, 
            {
                "arm_group_label": [
                    "efatutazone and paclitaxel", 
                    "paclitaxel"
                ], 
                "description": "Given IV", 
                "intervention_name": "paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxol"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 30, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Phase 2 Randomized Study of Efatutazone, an Oral PPAR Agonist, in Combination With Paclitaxel Versus Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Robert Smallridge, M.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: NCI Central Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall Survival", 
            "safety_issue": "No", 
            "time_frame": "Up to 5 years post-randomization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02152137"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Confirmed response rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years post-randomization"
            }, 
            {
                "measure": "Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years post- randomization"
            }, 
            {
                "measure": "Incidence of adverse events, graded according to Common Terminology Criteria for Adverse Events  version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 years post- randomization"
            }
        ], 
        "source": "Alliance for Clinical Trials in Oncology", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Daiichi Sankyo Inc.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Alliance for Clinical Trials in Oncology", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}